Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.

AOU Policlinico Rodolico San Marco Catania Italy

ASST Grande Ospedale Metropolitano Niguarda Milan Italy

Azienda Ospedaliera Sant'Anna e San Sebastiano Caserta Italy

Azienda Sanitaria Universitaria del Friuli Centrale Udine Italy

CIBERINFEC Instituto de Salud Carlos 3 Madrid Spain

Comenius University and National Cancer Institute Bratislava Slovakia

CRA From CRC Centre Hospitalier Victor DUPOUY Argenteuil France

Croatian Cooperative Group for Hematological Diseases Zagreb Croatia

Department of Clinical Microbiology Maria Skłodowska Curie National Research Institute of Oncology Warszawa Poland

Department of Haematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Health Sciences University of Genoa Genoa Italy

Department of Hematology and Oncology Comprehensive Cancer Center Innsbruck Innsbruck Austria

Department of Hematology and Oncology Hospital Morales Messeguer Murcia Spain

Department of Hematology Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University Wroclaw Poland

Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Department of Hematology Research Unit Hospital Universitario de Burgos Burgos Spain

Department of Hematology South Division of Internal Medicine Clinic Albert Szent Györgyi Health Center University of Szeged Szeged Hungary

Department of Hematology University Hospital Virgen Macarena University Hospital Virgen del Rocío Instituto de Biomedicina de Sevilla Seville Spain

Department of Infectious Diseases and Clinical Microbiology Faculty of Medicine Eskisehir Osmangazi University Eskisehir Turkey

Department of Infectious Diseases Hospital Clinic de Barcelona University of Barcelona IDIBAPS Barcelona Spain

Department of Internal Medicine ADRZ Goes Netherlands

Department of Internal Medicine Hematology and Oncology Masaryk University and University Hospital Brno Brno Czech Republic

Department of Mental Health and Public Medicine Universitry of Campania Naples Italy

Department of Nephrology and Infectious Diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium

Department of Oncology Hematology and Bone Marrow Transplantation With Section of Pneumology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Pediatric Oncology Children's Cancer Hospital Cairo Egypt

Department of Pediatric Oncology National Cancer Institute Cairo University Cairo Egypt

Division of Hematology Department of Internal Medicine Faculty of Medicine Istanbul University Istanbul Turkey

Division of Hematology Department of Internal Medicine University of Debrecen Debrecen Hungary

Ematologia Con Trapianto Ospedale Dimiccoli Barletta Barletta Italy

Faculty of Medicine Mansoura University Mansoura Egypt

Faculty of Medicine University of Cologne and University Hospital Cologne Clinical Trials Centre Cologne Cologne Germany

Faculty of Medicine University of Cologne and University Hospital Cologne Institute of Translational Research Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases Cologne Germany

Faculty of Medicine University of Cologne University Hospital Cologne Department 1 of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany

Faculty of Medicine University of Zagreb Zagreb Croatia

Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD Madrid Spain

General Hospital of Thessaloniki George Papanikolaou Thessaloniki Greece

German Centre for Infection Research partner Site Bonn Cologne Cologne Germany

Gomel State Medical University Gomel Belarus

Head ICU and CRC Centre Hospitalier Victor DUPOUY Argenteuil France

Hematology and Bone Marrow Unit Hospital University of Parma Parma Italy

Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy

Hematology and Stem Cell Transplantation Unit AOUC Policlinico Bari Italy

Hematology and Transplant Unit Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy

Hematology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy

Hematology Unit ASST Spedali Civili Brescia Italy

Hematology Unit Center for Translational Medicine AziendaUSL Toscana NordOvest Livorno Italy

Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

Hematology Unit Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori IRCCS Meldola Italy

Hematology Unit Università Cattolica del Sacro Cuore Rome Italy

Hospital Nuestra Señora de Sonsoles Ávila Spain

Hospital Rey Juan Carlos Móstoles Spain

IRCCS Ospedale San Raffaele Milan Italy

King Faisal Specialist Hospital Jeddah Saudi Arabia

Laikon Hospital Medical School National and Kapodistrian University of Athens Athens Greece

Maria Skłodowska Curie Institute of Oncology Warszawa Poland

McGill University Health Centre Montreal Canada

Medical University of Warsaw Warszawa Poland

Medizinische Klinik 2 Klinikum Rechts der Isar TU München Munich Germany

Microbiology and Parasitology Department University Hospital La Paz Madrid Spain

National Cancer Institute Fondazione 'G Pascale' IRCCS Hematology Oncology and Stem Cell Transplantation Unit Naples Italy

North Western State Medical University Named After Iliá Ilich Méchnikov Saint Petersburg Russia

Northumbria Healthcare Newcastle UK

Ospedale Vito Fazzi Lecce Italy

Servicio de Hematología y Hemoterapia Hospital Universitario Príncipe de Asturias Alcalá de Henares Spain

Stem Cell Transplant Center AOU Cittá della Salute e della Scienza Turin Italy

University Clinic of Hematology Skopje North Macedonia

University Clinical Center of Serbia Belgrade Serbia

University Hospital Centre Zagreb Zagreb Croatia

University Hospital Hradec Králové Hradec Králové Czech Republic

University Hospital Olomouc Olomouc Czech Republic

University Medical Center Groningen Groningen The Netherlands

University Medical Center Hamburg Eppendorf Hamburg Germany

University of Kansas Medical Center Kansas City Missouri USA

UO Clinica Malattie Infettive IRCCS Ospedale Policlinico San Martino Genoa Italy

Zobrazit více v PubMed

Martino R., Ramila E., Rabella N., et al., “Respiratory Virus Infections in Adults With Hematologic Malignancies: A Prospective Study,” Clinical Infectious Diseases 36, no. 1 (2003): 1–8. PubMed PMC

Gabutti G., De Motoli F., Sandri F., Toffoletto M. V., and Stefanati A., “Viral Respiratory Infections in Hematological Patients,” Infectious Diseases and Therapy 9, no. 3 (2020): 495–510. PubMed PMC

Fontana L. and Strasfeld L., “Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient,” Infectious Disease Clinics of North America 33, no. 2 (2019): 523–544. PubMed PMC

Popescu C. M., Ursache A. L., Feketea G., et al., “Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?,” Microorganisms 7, no. 11 (2019): 521. PubMed PMC

von Lilienfeld‐Toal M., Berger A., Christopeit M., et al., “Community Acquired Respiratory Virus Infections in Cancer Patients‐Guideline on Diagnosis and Management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology,” European Journal of Cancer 67 (2016): 200–212. PubMed PMC

Hirsch H. H., Martino R., Ward K. N., Boeckh M., Einsele H., and Ljungman P., “Fourth European Conference on Infections in Leukaemia (ECIL‐4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus,” Clinical Infectious Diseases 56, no. 2 (2013): 258–266. PubMed PMC

Engelhard D., Mohty B., de la Camara R., Cordonnier C., and Ljungman P., “European Guidelines for Prevention and Management of Influenza in Hematopoietic Stem Cell Transplantation and Leukemia Patients: Summary of ECIL‐4 (2011), on Behalf of ECIL, a Joint Venture of EBMT, EORTC, ICHS, and ELN,” Transplant Infectious Disease 15, no. 3 (2013): 219–232. PubMed

Salmanton‐Garcia J., Busca A., Cornely O. A., et al., “EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID‐19,” Hema 5, no. 7 (2021): e612. PubMed PMC

Aiello T. F., Salmanton‐Garcia J., Marchesi F., et al., “Dexamethasone Treatment for COVID‐19 Is Related to Increased Mortality in Hematologic Malignancy Patients: Results From the EPICOVIDEHA Registry,” Haematologica 109, no. 8 (2024): 2693–2700. PubMed PMC

Blennow O., Salmanton‐Garcia J., Nowak P., et al., “Outcome of Infection With Omicron SARS‐CoV‐2 Variant in Patients With Hematological Malignancies: An EPICOVIDEHA Survey Report,” American Journal of Hematology 97, no. 8 (2022): E312–E317. PubMed PMC

Busca A., Salmanton‐Garcia J., Marchesi F., et al., “Outcome of COVID‐19 in Allogeneic Stem Cell Transplant Recipients: Results From the EPICOVIDEHA Registry,” Frontiers in Immunology 14 (2023): 1125030. PubMed PMC

Cattaneo C., Salmanton‐Garcia J., Marchesi F., et al., “Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey,” Cancers (Basel) 14, no. 22 (2022): 5530. PubMed PMC

Criscuolo M., Salmanton‐Garcia J., Fracchiolla N., et al., “SARS‐CoV‐2 Infection in Patients With Mastocytosis: An EPICOVIDEHA Report,” Journal of Investigational Allergology & Clinical Immunology 33, no. 3 (2023): 225–227. PubMed

El‐Ashwah S., Salmanton‐Garcia J., Bilgin Y. M., et al., “The Mortality of COVID‐19 in CML Patients From 2020 Until 2022: Results From the EPICOVIDEHA Survey,” Leukemia & Lymphoma 65, no. 2 (2024): 199–208. PubMed

Infante M. S., Salmanton‐Garcia J., Fernandez‐Cruz A., et al., “B‐Cell Malignancies Treated With Targeted Drugs and SARS‐CoV‐2 Infection: A European Hematology Association Survey (EPICOVIDEHA),” Frontiers in Oncology 12 (2022): 992137. PubMed PMC

Lahmer T., Salmanton‐Garcia J., Marchesi F., et al., “Need for ICU and Outcome of Critically Ill Patients With COVID‐19 and Haematological Malignancies: Results From the EPICOVIDEHA Survey,” Infection 52, no. 3 (2024): 1125–1141. PubMed PMC

Lamure S., Salmanton‐Garcia J., Robin‐Marieton E., et al., “COVID‐19 and Hairy‐Cell Leukemia: An EPICOVIDEHA Survey,” Blood Advances 6, no. 13 (2022): 3870–3874. PubMed PMC

Marchesi F., Salmanton‐Garcia J., Buquicchio C., et al., “Passive Pre‐Exposure Immunization by Tixagevimab/Cilgavimab in Patients With Hematological Malignancy and COVID‐19: Matched‐Paired Analysis in the EPICOVIDEHA Registry,” Journal of Hematology & Oncology 16, no. 1 (2023): 32. PubMed PMC

Marchesi F., Salmanton‐Garcia J., Emarah Z., et al., “COVID‐19 in Adult Acute Myeloid Leukemia Patients: A Long‐Term Follow‐Up Study From the European Hematology Association Survey (EPICOVIDEHA),” Haematologica 108, no. 1 (2023): 22–33. PubMed PMC

Marchetti M., Salmanton‐Garcia J., El‐Ashwah S., et al., “Outcomes of SARS‐CoV‐2 Infection in Ph‐Neg Chronic Myeloproliferative Neoplasms: Results From the EPICOVIDEHA Registry,” Therapeutic Advances in Hematology 14 (2023): 20406207231154706. PubMed PMC

Musto P., Salmanton‐Garcia J., Sgherza N., et al., “Survival in Multiple Myeloma and SARS‐COV‐2 Infection Through the COVID‐19 Pandemic: Results From the EPICOVIDEHA Registry,” Hematological Oncology 42, no. 1 (2024): e3240. PubMed

Pagano L., Salmanton‐Garcia J., Marchesi F., et al., “Breakthrough COVID‐19 in Vaccinated Patients With Hematologic Malignancies: Results From the EPICOVIDEHA Survey,” Blood 140, no. 26 (2022): 2773–2787. PubMed PMC

Pagano L., Salmanton‐Garcia J., Marchesi F., et al., “COVID‐19 Infection in Adult Patients With Hematological Malignancies: A European Hematology Association Survey (EPICOVIDEHA),” Journal of Hematology & Oncology 14, no. 1 (2021): 168. PubMed PMC

Rossi G., Salmanton‐Garcia J., Cattaneo C., et al., “Age, Successive Waves, Immunization, and Mortality in Elderly COVID‐19 Hematological Patients: EPICOVIDEHA Findings,” International Journal of Infectious Diseases 137 (2023): 98–110. PubMed

Salmanton‐Garcia J., Marchesi F., Farina F., et al., “Decoding the Historical Tale: COVID‐19 Impact on Haematological Malignancy Patients‐EPICOVIDEHA Insights From 2020 to 2022,” EClinicalMedicine 71 (2024): 102553. PubMed PMC

Salmanton‐Garcia J., Marchesi F., Glenthoj A., et al., “Improved Clinical Outcome of COVID‐19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti‐SARS‐CoV‐2 Vaccine: An EPICOVIDEHA Report,” Hema 6, no. 11 (2022): e789. PubMed PMC

Salmanton‐Garcia J., Marchesi F., Gomes da Silva M., et al., “Nirmatrelvir/Ritonavir in COVID‐19 Patients With Haematological Malignancies: A Report From the EPICOVIDEHA Registry,” EClinicalMedicine 58 (2023): 101939. PubMed PMC

Salmanton‐Garcia J., Marchesi F., Koehler P., et al., “Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID‐19 in High‐Risk Patients With Haematological Malignancy in Europe. A Matched‐Paired Analysis From the EPICOVIDEHA Registry,” International Journal of Antimicrobial Agents 62, no. 4 (2023): 106952. PubMed

van Doesum J. A., Salmanton‐Garcia J., Marchesi F., et al., “Impact of SARS‐CoV‐2 Vaccination and Monoclonal Antibodies on Outcome Post‐CD19‐Directed CAR T‐Cell Therapy: An EPICOVIDEHA Survey,” Blood Advances 7, no. 11 (2023): 2645–2655. PubMed PMC

Salmanton‐Garcia J., Marchesi F., Itri F., et al., “Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients,” Hema 7, no. 11 (2023): e970. PubMed PMC

Garcia‐Arroyo L., Prim N., Del Cuerpo M., et al., “Prevalence and Seasonality of Viral Respiratory Infections in a Temperate Climate Region: A 24‐Year Study (1997‐2020),” Influenza and Other Respiratory Viruses 16, no. 4 (2022): 756–766. PubMed PMC

Atalla E., Kalligeros M., Mylona E. K., et al., “Impact of Influenza Infection Among Adult and Pediatric Populations With Hematologic Malignancy and Hematopoietic Stem Cell Transplant: A Systematic Review and Meta‐Analysis,” Clinical Therapeutics 43, no. 5 (2021): e66–e85. PubMed

Kaku Y., Okumura K., Padilla‐Blanco M., et al., “Virological Characteristics of the SARS‐CoV‐2 JN.1 Variant,” Lancet Infectious Diseases 24, no. 2 (2024): e82. PubMed

Goldberg Y. and Huppert A., “To Boost or Not to Boost: Navigating Post‐Pandemic COVID‐19 Vaccination,” Lancet Respiratory Medicine 11, no. 12 (2023): 1039–1041. PubMed

Lazarus J. V., White T. M., Wyka K., et al., “Influence of COVID‐19 on Trust in Routine Immunization, Health Information Sources and Pandemic Preparedness in 23 Countries in 2023,” Nature Medicine 30, no. 6 (2024): 1559–1563. PubMed PMC

Liu C., Huang J., Chen S., et al., “The Impact of Crowd Gatherings on the Spread of COVID‐19,” Environmental Research 213 (2022): 113604. PubMed PMC

Gur‐Arie L., Stein M., Sefty H., et al., “Hospital Surveillance of Respiratory Viruses During the COVID‐19 Pandemic and Beyond: Contribution to the WHO Mosaic Framework, Israel, 2020 to 2023,” Euro Surveillance 29, no. 32 (2024): 2300634. PubMed PMC

Chemaly R. F., Shah D. P., and Boeckh M. J., “Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies,” Clinical Infectious Diseases 59, no. Suppl 5 (2014): S344–S351. PubMed PMC

Lee S. S., Viboud C., and Petersen E., “Understanding the Rebound of Influenza in the Post COVID‐19 Pandemic Period Holds Important Clues for Epidemiology and Control,” International Journal of Infectious Diseases 122 (2022): 1002–1004. PubMed PMC

Pendrey C. G., Strachan J., Peck H., et al., “The re‐Emergence of Influenza Following the COVID‐19 Pandemic in Victoria, Australia, 2021 to 2022,” Euro Surveillance 28, no. 37 (2023): 2300118. PubMed PMC

CDC: Centers for Disease Control and Prevention , “Immunization Recommendations for the 2023–2024 Respiratory Disease Season: At‐A‐Glance11/24/2023 CS‐343797A INFLUENZA • COVID‐19 • RSV,” (2023), https://www.cdc.gov/respiratory‐viruses/tools‐resources/downloads/respiratory‐disease‐at‐a‐glance‐508.pdf.

Das Barshan A. and Matsumoto‐Takahashi E. L. A., “Efficacy of COVID‐19 Vaccines in Patients With Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta‐Analysis,” Japan Medical Association Journal 7, no. 2 (2024): 153–171. PubMed PMC

Lai C. C., Chen I. T., Chao C. M., Lee P. I., Ko W. C., and Hsueh P. R., “COVID‐19 Vaccines: Concerns Beyond Protective Efficacy and Safety,” Expert Review of Vaccines 20, no. 8 (2021): 1013–1025. PubMed

Cesaro S., Mikulska M., Hirsch H. H., et al., “Update of Recommendations for the Management of COVID‐19 in Patients With Haematological Malignancies, Haematopoietic Cell Transplantation and CAR T Therapy, From the 2022 European Conference on Infections in Leukaemia (ECIL 9),” Leukemia 37, no. 9 (2023): 1933–1938. PubMed PMC

La E. M., Bunniran S., Garbinsky D., et al., “Respiratory Syncytial Virus Knowledge, Attitudes, and Perceptions Among Adults in the United States,” Human Vaccines and Immunotherapeutics 20, no. 1 (2024): 2303796. PubMed PMC

Schumacher S., Salmanton‐Garcia J., Liekweg A., et al., “Increasing Influenza Vaccination Coverage in Healthcare Workers: Analysis of an Intensified on‐Site Vaccination Campaign During the COVID‐19 Pandemic,” Infection 51, no. 5 (2023): 1417–1429. PubMed PMC

Schumacher S., Salmanton‐Garcia J., Cornely O. A., and Mellinghoff S. C., “Increasing Influenza Vaccination Coverage in Healthcare Workers: A Review on Campaign Strategies and Their Effect,” Infection 49, no. 3 (2021): 387–399. PubMed PMC

Cremer L. M., Bethe B., Borchmann P., et al., “Immunogenicity of COVID‐19 Vaccination in Immunocompromised Patients (Auto‐COVID‐VACC): Protocol for a Multicenter Prospective Non‐Interventional Study,” JMIR Research Protocols (2024).

Mulroney C. M., Abid M. B., Bashey A., et al., “Incidence and Impact of Community Respiratory Viral Infections in Post‐Transplant Cyclophosphamide‐Based Graft‐Versus‐Host Disease Prophylaxis and Haploidentical Stem Cell Transplantation,” British Journal of Haematology 194, no. 1 (2021): 145–157. PubMed PMC

Vakil E. and Evans S. E., “Viral Pneumonia in Patients With Hematologic Malignancy or Hematopoietic Stem Cell Transplantation,” Clinical Chest Medicine 38, no. 1 (2017): 97–111. PubMed PMC

Shah J. N. and Chemaly R. F., “Management of RSV Infections in Adult Recipients of Hematopoietic Stem Cell Transplantation,” Blood 117, no. 10 (2011): 2755–2763. PubMed

Shah D. P., Shah P. K., Azzi J. M., El Chaer F., and Chemaly R. F., “Human Metapneumovirus Infections in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients: A Systematic Review,” Cancer Letters 379, no. 1 (2016): 100–106. PubMed PMC

Shah D. P., Shah P. K., Azzi J. M., and Chemaly R. F., “Parainfluenza Virus Infections in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients: A Systematic Review,” Cancer Letters 370, no. 2 (2016): 358–364. PubMed PMC

Unal S., Schnitzler P., Giesen N., Wedde M., Durrwald R., and Tabatabai J., “Molecular Epidemiology and Disease Severity of Influenza Virus Infection in Patients With Haematological Disorders,” Journal of Medical Virology 95, no. 6 (2023): e28835. PubMed

Tabatabai J., Schnitzler P., Prifert C., et al., “Parainfluenza Virus Infections in Patients With Hematological Malignancies or Stem Cell Transplantation: Analysis of Clinical Characteristics, Nosocomial Transmission and Viral Shedding,” PLoS One 17, no. 7 (2022): e0271756. PubMed PMC

Khawaja F. and Chemaly R. F., “Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies,” Haematologica 104, no. 7 (2019): 1322–1331. PubMed PMC

Lefeuvre C., Salmona M., Bondeelle L., et al., “Frequent Lower Respiratory Tract Disease in Hematological Patients With Parainfluenza Virus Type 3 Infection,” Journal of Medical Virology 93, no. 11 (2021): 6371–6376. PubMed

Pochon C. and Voigt S., “Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients,” Frontiers in Microbiology 9 (2018): 3294. PubMed PMC

Hakim H., Dallas R., Zhou Y., et al., “Acute Respiratory Infections in Children and Adolescents With Acute Lymphoblastic Leukemia,” Cancer 122, no. 5 (2016): 798–805. PubMed PMC

Vanderbeke L., Spriet I., Breynaert C., Rijnders B. J. A., Verweij P. E., and Wauters J., “Invasive Pulmonary Aspergillosis Complicating Severe Influenza: Epidemiology, Diagnosis and Treatment,” Current Opinion in Infectious Diseases 31, no. 6 (2018): 471–480. PubMed

Goka E., Vallely P., Mutton K., and Klapper P., “Influenza A Viruses Dual and Multiple Infections With Other Respiratory Viruses and Risk of Hospitalisation and Mortality,” Influenza and Other Respiratory Viruses 7, no. 6 (2013): 1079–1087. PubMed PMC

Garcia‐Vidal C., Barba P., Arnan M., et al., “Invasive Aspergillosis Complicating Pandemic Influenza A (H1N1) Infection in Severely Immunocompromised Patients,” Clinical Infectious Diseases 53, no. 6 (2011): e16–e19. PubMed

Schauwvlieghe A., Rijnders B. J. A., Philips N., et al., “Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Severe Influenza: A Retrospective Cohort Study,” Lancet Respiratory Medicine 6, no. 10 (2018): 782–792. PubMed

Rachow T., Lamik T., Kalkreuth J., et al., “Detection of Community‐Acquired Respiratory Viruses in Allogeneic Stem‐Cell Transplant Recipients and Controls—A Prospective Cohort Study,” Transplant Infectious Disease 22, no. 6 (2020): e13415. PubMed PMC

Sanli K., Ayer M., Alacam S., Gumus A., and Karabulut N., “Retrospective Analysis of Respiratory Virus Infections in Adults With Hematologic Malignancies,” European Review for Medical and Pharmacological Sciences 27, no. 21 (2023): 10785–10797. PubMed

Abbas S., Raybould J. E., Sastry S., and de la Cruz O., “Respiratory Viruses in Transplant Recipients: More Than Just a Cold. Clinical Syndromes and Infection Prevention Principles,” International Journal of Infectious Diseases 62 (2017): 86–93. PubMed